

For E-book, see
inside front cover

Handbook of
**PROSTATE CANCER
AND OTHER
GENITOURINARY
MALIGNANCIES**

**TERESA GRAY HAYES
MARTHA PRITCHETT MIMS
JENNIFER MARIE TAYLOR**



demosMEDICAL

Handbook of Prostate Cancer and Other Genitourinary Malignancies

Editors

Teresa Gray Hayes, MD, PhD

*Associate Professor of Medicine, Emeritus
Internal Medicine/Hematology-Oncology
Baylor College of Medicine
Houston, Texas*

Martha Pritchett Mims, MD, PhD

*Associate Professor and Chief of Hematology and Oncology
Internal Medicine/Hematology-Oncology
Baylor College of Medicine
Houston, Texas*

Jennifer Marie Taylor, MD, MPH

*Assistant Professor
Urology
Baylor College of Medicine;
Staff Surgeon, Urology
Michael E. DeBakey VA Medical Center
Houston, Texas*



demosMEDICAL
New York

Visit our website at www.demosmedical.com

ISBN: 9781620701096

e-book ISBN: 9781617052866

Acquisitions Editor: David D'Addona

Compositor: diacriTech

Copyright © 2017 Springer Publishing Company.

Demos Medical Publishing is an imprint of Springer Publishing Company, LLC.

All rights reserved. This book is protected by copyright. No part of it may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, recording, or otherwise, without the prior written permission of the publisher.

Medicine is an ever-changing science. Research and clinical experience are continually expanding our knowledge, in particular our understanding of proper treatment and drug therapy. The authors, editors, and publisher have made every effort to ensure that all information in this book is in accordance with the state of knowledge at the time of production of the book. Nevertheless, the authors, editors, and publisher are not responsible for errors or omissions or for any consequences from application of the information in this book and make no warranty, expressed or implied, with respect to the contents of the publication. Every reader should examine carefully the package inserts accompanying each drug and should carefully check whether the dosage schedules mentioned therein or the contraindications stated by the manufacturer differ from the statements made in this book. Such examination is particularly important with drugs that are either rarely used or have been newly released on the market.

Library of Congress Cataloging-in-Publication Data

Names: Hayes, Teresa Gray, editor. | Mims, Martha Pritchett, editor. | Taylor, Jennifer Marie, editor.

Title: Handbook of prostate cancer and other genitourinary malignancies / editors, Teresa Gray Hayes, Martha Pritchett Mims, Jennifer Marie Taylor.

Description: New York: Demos Medical, [2017] | Includes bibliographical references and index.

Identifiers: LCCN 2017013587 | ISBN 9781620701096 | ISBN 9781617052866

Subjects: | MESH: Prostatic Neoplasms | Urogenital Neoplasms

Classification: LCC RC280.P7 | NLM WJ 762 | DDC 616.99/463—dc23

LC record available at <https://lccn.loc.gov/2017013587>

Contact us to receive discount rates on bulk purchases.

We can also customize our books to meet your needs.

For more information please contact: sales@springerpub.com

Printed in the United States of America by McNaughton & Gunn.

17 18 19 20 / 5 4 3 2 1

**Handbook of
Prostate Cancer and Other
Genitourinary Malignancies**

*To our patients, who have taught us so much; and to our
trainees, who have worked so hard to ensure that our patients
get the best care possible.*

Preface

Genitourinary malignancies represent a wide spectrum of risk and prognosis. The last decade or more has brought an extraordinary evolution in outcomes for patients with these diseases at advanced stages, mainly through development and adoption of new systemic therapies. In addition, greater attention is being paid to comprehensive assessment of the patient before, during, and after treatment. More systematic measurement of influential medical and psychosocial factors has allowed for better treatment selection and symptom management.

This handbook aims to provide a broad overview and current summary of the state of assessment, diagnosis, and treatment of these malignancies. It will be useful for clinicians at multiple stages in medical and surgical specialties: in training, early in a career, and looking for updated information. With the ability to reference quickly for a specific question, or review a larger section all at once, the reader can customize the depth with which he or she uses the handbook.

This remains an exciting time for those dealing with many of these malignancies, with advances and innovations continuing in both the medical and surgical arenas. The dissemination of these developments and collaboration among specialists will continue to bring improved outcomes to our patients living with or surviving these diseases. We are grateful to the patients and providers who work together in clinical trials, which are the foundation of the progress and drive the evolution of the field forward.

We welcome your feedback and suggestions as you use this handbook in practice.

Jennifer Marie Taylor, MD, MPH

Acknowledgments

The authors would like to acknowledge Baylor College of Medicine and the Michael E. DeBakey VA Medical Center, Houston, Texas, for their support and assistance.

Contents

<i>Contributors</i>	xi
<i>Preface</i>	xv
<i>Acknowledgments</i>	xvii

I. Prostate Cancer

EARLY STAGE PROSTATE CANCER

1. Prostate Cancer Screening 3
Thiri Khin and Nicholas Mitsiades
2. Management of Early Stage Prostate Cancer 9
Pranav Dadhich and Jennifer Marie Taylor
3. Early Stage Prostate Cancer: Biochemical Relapse 21
Andrew Jackson and Teresa Gray Hayes
4. Intermittent Androgen Ablation in Biochemical Relapse of Early Stage Prostate Cancer 27
Chitra Balasundaram and Teresa Gray Hayes
5. Treatment of Therapy Complications 33
Pranav Dadhich and Jennifer Marie Taylor
6. Early Stage Prostate Cancer: Controversies in Management 37
Jianbo Wang and Teresa Gray Hayes
7. Early Stage Prostate Cancer Survivorship Challenges 43
Andrew Jackson and Teresa Gray Hayes

MANAGEMENT OF ADVANCED PROSTATE CANCER

8. Treatment of Metastatic Cancer: Hormonal Agents, Chemotherapy, Immune Modulation, and Radiopharmaceuticals 47
Jesus H. Hermosillo-Rodriguez and Teresa Gray Hayes
9. Intermittent Androgen Ablation in Metastatic Prostate Cancer 59
Abhishek Marballi and Teresa Gray Hayes

10. Bone Health and Use of Adjunctive Agents 65
Jesus H. Hermosillo-Rodriguez and Nicholas Mitsiades
11. Advanced Stage Prostate Cancer: Controversies
in Management 69
Jesus H. Hermosillo-Rodriguez and Nicholas Mitsiades
12. Advanced Prostate Cancer Survivorship Challenges and
Issues 73
Jesus H. Hermosillo-Rodriguez and Nicholas Mitsiades

II. Other Genitourinary Malignancies

KIDNEY CANCER

13. Kidney Cancer: Histologic Subtypes and
Genetic Syndromes 79
Thiri Khin and Teresa Gray Hayes
14. Treatment of Early Stage Renal Cell Carcinoma:
Surgical Approaches, Partial Nephrectomy, and Ablation 89
Friedrich-Carl von Rundstedt, Wesley A. Mayer, and Richard E. Link
15. Renal Cell Carcinoma: Treatment of Advanced
Kidney Cancer 97
Kanza S. Abbas and Teresa Gray Hayes
16. Controversies in the Surgical Management of Renal
Cell Carcinoma 103
Thomas E. Stout and Samit D. Soni
17. Investigational Technologies in the Surgical Management of
Renal Cell Carcinoma 113
Thomas E. Stout and Samit D. Soni
18. Kidney Cancer Survivorship Challenges and Issues 117
Elaine Chang and Wesley A. Mayer

UPPER TRACT UROTHELIAL CANCER

19. Overview of Upper Tract Urothelial Cancers 123
Harish Madala, Carli Calderone, and Wesley A. Mayer
20. Management of Early Stage Upper Tract Urothelial Cancers 135
Harish Madala, Carli Calderone, and Wesley A. Mayer
21. Treatment of Metastatic Upper Tract Urothelial Cancers 141
Jose Pacheco, Saleha Sajid, and Teresa Gray Hayes
22. Controversies in the Management of Upper Tract
Urothelial Cancer 147
Jose Pacheco and Jennifer Marie Taylor

23. Upper Tract Urothelial Carcinoma Survivorship 153
Spencer Craven and Jennifer Marie Taylor

BLADDER CANCER

24. Urothelial Cancer of the Bladder: Treatment of Early Stage Disease 157
Carli Calderone and Jennifer Marie Taylor
25. Management of Invasive Bladder Cancer: Surgery, Chemotherapy, and Radiation Therapy 177
Arun Rai, Thiri Khin, Teresa Gray Hayes, and Jennifer Marie Taylor
26. Treatment of Metastatic Bladder Cancer: Chemotherapy and Checkpoint Inhibitors 197
Jose Pacheco and Teresa Gray Hayes
27. Controversies in the Management of Bladder Cancer 203
Jose Pacheco and Teresa Gray Hayes
28. Bladder Cancer Surveillance and Survivorship 209
Bethany R. Desroches and Jennifer Marie Taylor

TESTICULAR CANCER

29. Seminomas 215
Mehmet Akce and Teresa Gray Hayes
30. Nonseminomatous Germ Cell Tumors: Early Stage, Late Stage 225
Ryan Yates and Martha Pritchett Mims
31. Reproductive Considerations and Long-Term Complications of Therapy 235
Thiri Khin and Martha Pritchett Mims
32. Controversies in the Management of Testicular Cancer 243
Ghana Kang and Martha Pritchett Mims

PENILE CANCER

33. Treatment of Early Stage Penile Cancer 251
Guilherme Godoy
34. Treatment of Metastatic Penile Cancer: Chemotherapy 267
Abhishek Marballi and Teresa Gray Hayes
35. Controversies in the Management of Penile Cancer 273
Guilherme Godoy
36. Penile Cancer Survivorship Challenges and Issues 279
Spencer Craven and Guilherme Godoy

Contributors

Kanza S. Abbas, MD

Clinical Postdoctoral Fellow
Internal Medicine/
Hematology-Oncology
Baylor College of Medicine,
Houston, Texas
Now at Kelsey Seybold Clinic,
Houston, Texas

Mehmet Akce, MD

Clinical Postdoctoral Fellow
Internal Medicine/
Hematology-Oncology
Baylor College of Medicine,
Houston, Texas

Chitra Balasundaram, MD

Clinical Postdoctoral Fellow
Internal Medicine/
Hematology-Oncology
Baylor College of Medicine,
Houston, Texas
Now at Mercy Clinic Cancer
and Hematology,
Springfield, Missouri

Carli Calderone, MD

Medical Resident
Urology
Emory University,
Atlanta, Georgia

Elaine Chang, MD

Clinical Postdoctoral Fellow
Internal Medicine/
Hematology-Oncology
Baylor College of Medicine,
Houston, Texas

Spencer Craven, MD

Medical Resident
Urology
Baylor College of Medicine,
Houston, Texas

Pranav Dadhich, MD

Medical Student
Urology
Baylor College of Medicine,
Houston, Texas

Bethany R. Desroches, MD

Medical Resident
Urology
Baylor College of Medicine,
Houston, Texas

Guilherme Godoy, MD

Assistant Professor
Urology
Baylor College of Medicine,
Houston, Texas

Teresa Gray Hayes, MD, PhD
Associate Professor of Medicine,
Emeritus
Internal Medicine/
Hematology-Oncology
Baylor College of Medicine,
Houston, Texas

**Jesus H. Hermosillo-
Rodriguez, MD**
Clinical Postdoctoral Fellow
Internal Medicine/
Hematology-Oncology
Baylor College of Medicine,
Houston, Texas
Now at Colorado Permanente
Medical Group,
Denver, Colorado

Andrew Jackson, MD
Clinical Postdoctoral Fellow
Internal Medicine/
Hematology-Oncology
Baylor College of Medicine,
Houston, Texas

Ghana Kang, MD
Clinical Postdoctoral Fellow
Internal Medicine/
Hematology-Oncology
Baylor College of Medicine,
Houston, Texas
Now at Northern Virginia
Hematology Associates,
Woodbridge, Virginia

Thiri Khin, MD
Clinical Postdoctoral Fellow
Internal Medicine/
Hematology-Oncology
Baylor College of Medicine,
Houston, Texas

Richard E. Link, MD
Associate Professor
Urology
Baylor College of Medicine,
Houston, Texas

Harish Madala, MD
Clinical Postdoctoral Fellow
Internal Medicine/
Hematology-Oncology
Baylor College of Medicine,
Houston, Texas

Abhishek Marballi, MD
Clinical Postdoctoral Fellow
Internal Medicine/
Hematology-Oncology
Baylor College of Medicine,
Houston, Texas
Now at Crystal Run
Healthcare,
Middletown, New York

Wesley A. Mayer, MD
Assistant Professor
Urology
Baylor College of Medicine,
Houston, Texas

**Martha Pritchett
Mims, MD, PhD**
Associate Professor and
Chief of Hematology and
Oncology
Internal Medicine/
Hematology-Oncology
Baylor College of Medicine,
Houston, Texas

Nicholas Mitsiades, MD
Assistant Professor
Internal Medicine/
Hematology-Oncology
Baylor College of Medicine,
Houston, Texas

Jose Pacheco, MD
Clinical Postdoctoral Fellow
Internal Medicine/
Hematology-Oncology
Baylor College of Medicine,
Houston, Texas

Arun Rai, MD

Medical Resident
Urology
Baylor College of Medicine,
Houston, Texas

Saleha Sajid, MBBS

Assistant Professor
Internal Medicine/
Hematology-Oncology
Baylor College of Medicine,
Houston, Texas
Now at Genesis Medical Group,
Woodlands, Texas

Samit D. Soni, MD

Assistant Professor
Urology
Baylor College of Medicine,
Houston, Texas

Thomas E. Stout, MD

Medical Student
Urology
Baylor College of Medicine,
Houston, Texas

Jennifer Marie Taylor, MD, MPH

Assistant Professor
Urology
Baylor College of Medicine;
Staff Surgeon
Michael E. DeBakey VA Medical
Center,
Houston, Texas

**Friedrich-Carl von
Rundstedt, MD**

Staff Physician
Urology
Jena University Hospital, Jena,
Thuringia, Germany

Jianbo Wang, MB, PhD

Clinical Postdoctoral Fellow
Internal Medicine/
Hematology-Oncology
Baylor College of Medicine,
Houston, Texas

Ryan Yates, MD

Clinical Postdoctoral Fellow
Internal Medicine/
Hematology-Oncology
Baylor College of Medicine,
Houston, Texas

Prostate Cancer



EARLY STAGE PROSTATE CANCER

Prostate Cancer Screening

1

Thiri Khin and Nicholas Mitsiades

INTRODUCTION

Prostate cancer is the most common visceral cancer in the United States and the second leading cause of cancer death after lung cancer. In the United States, approximately one in seven men will be diagnosed with prostate cancer. One in 39 prostate cancer patients will die from the disease. Survival of prostate cancer is related to many factors, including age and stage at diagnosis (1). Although the 5-year survival rate for early localized prostate cancer is 100%, survival is only 29.3% for distant metastatic disease.

With the goal of reducing cancer-related morbidity and mortality by early detection, screening strategies are employed in common and lethal cancers such as prostate cancer. Prostate-specific antigen (PSA) was initially developed as a tumor marker to assess the extent of disease and detect treatment response. Despite a lack of efficacy data from randomized controlled trials (RCTs), PSA was incorporated into prostate cancer screening in the early 1990s, which subsequently led to a peak increase in the detected incidence of prostate cancer. Most of the cancers detected were early stage disease, which otherwise would have not been discovered and may not have been clinically relevant. However, early detection often led to aggressive treatment. Since then, the benefits of PSA screening have been questioned and have been a major topic of debate among clinicians and guideline organizations.

VARIATIONS OF PSA LEVEL

PSA is a glycoprotein expressed in both normal and neoplastic prostatic epithelial tissue. The PSA level reflects the amount of prostate glandular epithelium in normal healthy men. Prostate size increases with age and in turn increases the PSA level. The PSA increases by 3.2% (0.04 ng/mL) per year for a 60-year old, and reference ranges for different age groups have been proposed.

In addition, multiple factors may influence the PSA level in healthy individuals. African American men have higher PSA levels when compared to White men. Prostatitis, perineal trauma, benign prostatic hypertrophy, prostate biopsy, and ejaculation can elevate the PSA level. Medications such as 5- α reductase inhibitors can reduce the PSA level by up to 50%. Nonsteroidal anti-inflammatory drugs (NSAIDs), acetaminophen, statins, and thiazide diuretics can lower the PSA level to varying degrees. Despite these variations, a traditional cutoff of 4 ng/mL or more has been considered abnormal by most clinicians.

PSA TESTING IN MALIGNANCY

PSA levels are raised in malignancy, not only due to increased production by malignant epithelial cells but also due to disruption of vasculature and release of PSA into the bloodstream. Multiple studies have shown that a rise in PSA precedes the development of prostate cancer by 5 to 10 years. Different cancers have varying levels of PSA elevation, and poorly differentiated cancer can have a large tumor burden with minimally elevated PSA.

Using a cutoff value of 4 ng/mL, the estimated sensitivity is 21% for detecting any prostate cancer and 51% for high-grade cancer in pooled analyses. Specificity is estimated to be 91%. Positive predictive value (PPV) is 30%, which means that one in three men with PSA more than 4 ng/mL has prostate cancer. Negative predictive value (NPV) is 85% for a PSA level lower than 4 ng/mL (2). Different strategies have been tested to improve the performance of PSA testing in prostate cancer. Lowering the cutoff level increases the sensitivity level but in turn reduces specificity. Various tests such as PSA velocity, PSA